Nuvalent, Inc.

Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from

Nuvation Bio has presented new pivotal trial data which could give its next-generation ROS1 inhibitor taletrectinib best-in-class status. But its rival and near-namesake Nuvalent is hot on its heel

Boehringer Ingelheim GmbH presented Phase Ib results and Bayer AG reported Phase I/II data for their HER2 inhibitors at World Conference on Lung Cancer (WCLC) that showed greater response rates for